Glutamine Metabolism Regulates CD4+ T Cell Inflammation in Metabolic Dysfunction-Associated Steatotic Liver Disease

Glutamine Metabolism Regulates CD4+ T Cell Inflammation in Metabolic Dysfunction-Associated Steatotic Liver Disease

Document Type

Poster

Publication Date

10-1-2025

Abstract

Metabolic dysfunction-associated steatotic liver disease (MASLD) is becoming increasingly prevalent worldwide. Yet, the knowledge of disease mechanisms and available therapies are highly limited. To better understand the disease and provide potential treatments, our lab utilized various mice and in vitro models in order to determine the effects of Glutamine (Gln) metabolism and its Gls1-mediated metabolic pathway on CD4+ T cell inflammatory functions. Combined, our findings and prior work in the lab demonstrate the crucial role of Gls1-mediated glutaminolysis in limiting hepatocellular damage and hepatic CD4+ T cell inflammatory capacity in MASLD, and provide novel insights for potential predictive, preventive, and therapeutic avenues.

Department

Department of Immunobiology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio

Project Mentor

Keisuke Sawada and Senad Divanovic

Funding and Acknowledgements

National Institute of Health, American Diabetes Association, American Heart Association, and CCHMC Albert B. Sabin Fellowship

Glutamine Metabolism Regulates CD4+ T Cell Inflammation in Metabolic Dysfunction-Associated Steatotic Liver Disease

Share

COinS